Pulmoner arteriyel hipertansiyon: patogenez

1.
Sa
k SD, Perçinel S. Pulmoner hipertansiyonda histopatolojik bulgular In: Karabıyıkoğlu G. ed. Pulmoner Hipertansiyon. Ankara: Antıp Basımevi; 2007;13-17
2. Said IS. Mediators and modulators ofpulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291(4): 547-58.
3.
Karabıyıkoğl
u G. Pulmoner arteryal hipertansiyon. In: Karabıyıkoğlu G. ed. Pulmoner Hipertansiyon. Ankara: Antıp Basımevi; 2007;112-30
4. Lee SH. Rubin LJ. Current treatmnet strategies for pulmonary arterial hypertension. J. Int. Med.2005;258(3):199-215
5. Travis WD, Colby TV, Koss MN, Rosado-de Christenson M, Müller NL, King TE. Pulmonary hypertension and other vascular disorders in nonneoplastic disorders ofthe lower respiratory tract. AFIP 2002;767-92
6.
Öne
n ZP, Karabıyıkoğlu G. Pulmoner damarların yeniden yapılanması. In: Karabıyıkoğlu G. ed. Pulmoner Hipertansiyon. Ankara: Antıp Basımevi; 2007; 18-25.
7. Li G, Chen SJ, Oparil S, Yiu-Fai C, Thompson JA. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblast after balon ofrat carotid arteries. Circulation 2000;101(12):1362-65
8. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. 2003;70 (Suppl 1): S 2-8
9. Loyd JE, Atkinson JB, Pietra GG,,. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 1988; 138(4):952-
57
10. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of80 cases. Mayo Clin Proc 1985; 60 (1):16-25
11. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, et al. Impact ofTASK-1 in human pulmoner artery smooth muscle cells. Circ Res. 2006;98(8):1072-80^
12. Piacentini L, Gray M, Honbo NY, Chentoufi J, Bergman M, Karliner JS. Endothelin-1 stimulates cardiac fibroblast proliferation through activation ofprotein kinase C. J Mol Cell Cardiol. 2000;32(4):565-76
13. Miyauchi T, Masaki T. Pathophysiology ofendothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391-415
14. Sirois MG, Filep JG, Rousseau A, Fournier A, Plante GE, Sirois P. Endothelin-1 enhances vascular permeability in conscious rats: role ofthromboxane A2. EurJPharmacol. 1992;214(2):119-25
15. Rae GA, Henriques MGMO. Endothelins in inflammation. In Said SI, ed. Proinflammatory and antiinflammatory peptides. New York: Marcel Dekker Inc; 1998:163-202
16. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-76
17. Dagassan PH, Breu V, Clozel M, Künzli A, Vogt P, Turina M, et al. Up-regulation ofendothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 1996;27(1):147-53
18. Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 2002;7(1):9-19
19. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role ofendothelin-LJInvestDermatol. 2001;116(3):417-25
20. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet 2002;360 (9337): 886-7
21. Dweik RA. The promise and reality ofnitric oxide in the diagnosis and treatment oflung disease. Cleve Clin JMed 2001; 68(6):486-93
22. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, et al. Biochemical reaction products ofnitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 158(3):917-23
23. Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels ofnitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung2001; 179(4):233-43
24. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68(9):782-95
25. Arroliga AC, Dweik RA, Kaneko FJ, Erzurum SC. Primary pulmonary hypertension: update on pathogenesis and novel therapies. Cleve Clin J Med 2000; 67(3):175-90
26. Dweik RA, Erzurum SC. Effects ofnitric oxide and cyclic GMP on smooth muscle proliferation. In: Moss J, ed. LAM and other diseases characterized by smooth muscle proliferation (Lung Biology in Health and Disease series). New York: Marcel Dekker, 1999;131:333-49
27. Dweik RA, Laskowski D, Abu-Soud HM, Kaneko F, Hutte R, Stuehr DJ, al. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. J Clin Invest 1998;101(3):660-66
28. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329(27):2002-12
29. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, andcontrols. Cell 1994;78(6): 915-18
30. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelialcells. Nature 1988; 332(6163):411-15
31. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression ofendothelin-1 in the lungs ofpatients with pulmonary hypertension. N Engl J Med 1993; 328(24):1732-39
32. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator ofdisease? Ann InternMed 1991;114(6): 464-69
33. Moncada S, Vane JR. Pharmacology and endogenous roles ofprostaglandin endoperoxides, thromboxane A2, andprostacyclin. PharmacolRev 1978; 30(3):293-
331
34. Gorman RR, Bunting S, Miller OV. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977;13(3):377-88
35. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development ofhypoxic pulmonary hypertension.JClinInvest 1999;103(11):1509-15
36. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-32
37. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ETA and ETB receptors modulate the proliferation ofhuman pulmonary artery smooth muscle cells. Am J Respir Crit Care 2002;165(3):398-405
38. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion ofthromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327(2):70-5
39. Das M, Dempsey EC, Bouchey D, Reyland MR, Stenmark KR. Chronic hypoxia induces aggregated growth responses in pulmonary arterial adventitial fibroblast. Am J Respir Crit Care Med 2000;22(1):15-
25
40. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110(3):710-17
41. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, MatsuoH, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192(2):553-60
42. Westphal M, Booke M, Dinh-Xuan AT. Adrenomedullin: a smart road from pheochromocytoma to treatment ofpulmonary hypertension. Eur Respir J 2004;24(4): 518-20
43. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest.1998;101(5):927-34
44. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67(3):737-44
45. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor in human disease. N Engl J Med 2000;342(18):1350-58
46. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, et al. Mutations ofthe TGF-type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27(2):121-32
47. Jason X, Yuan J, Rubin LJ. Pathogenesis ofpulmonary arterial hypertension. The need for multiple hits. Circulation 2005;111(5):534-38
48. Runo JR, Loyd JE. Primary pulmonary hypertension. 2003. Lancet 361(9368):1533-44
49. Derynck R, Zhang YE. Smad-dependent and Smadin-independent pathways in TGF-beta family signalling. Nature 2003;425(6958):577-84
50. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005;96(10):1053-63
51. Austin ED, Loyd JE. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 2007;
28(1):43-57
52. Elliott CG. Genetics ofpulmonary arterial hypertension: current and future implications. Semin Respir Crit Care Med 2005;26(4):365-71
53. Newman JH. Pulmonary hypertension. Am J Respir CritCareMed 2005;172(9): 1072-77
54. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004;287(6):1241-47